|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5849589A
(en)
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP4336452B2
(ja)
*
|
1997-12-08 |
2009-09-30 |
メルク パテント ゲーエムベーハー |
標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6864235B1
(en)
|
1999-04-01 |
2005-03-08 |
Eva A. Turley |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
|
WO2002024223A2
(en)
|
2000-09-21 |
2002-03-28 |
The Brigham And Women's Hospital, Inc. |
Prevention and treatment of streptococcal and staphylococcal infection
|
|
US8192744B2
(en)
|
2002-08-26 |
2012-06-05 |
Ibcc Holding As |
Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
|
|
JP4730304B2
(ja)
|
2004-05-20 |
2011-07-20 |
和光純薬工業株式会社 |
ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
|
|
US8044022B2
(en)
|
2005-06-08 |
2011-10-25 |
Tadeusz Kolodka |
Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
EP1999154B1
(en)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Engineered heterodimeric protein domains
|
|
WO2008018519A1
(fr)
|
2006-08-08 |
2008-02-14 |
Seikagaku Corporation |
Procédé de détermination du poids moléculaire d'un acide hyaluronique
|
|
WO2008089448A2
(en)
|
2007-01-19 |
2008-07-24 |
Cornell Presearch Foundation, Inc. |
Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
|
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
|
CA2720368C
(en)
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
|
EP2270145B1
(en)
|
2008-04-15 |
2013-01-16 |
Wako Pure Chemical Industries, Ltd. |
Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
|
|
US20120034212A1
(en)
|
2009-01-29 |
2012-02-09 |
Michael Bowen |
Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
|
|
PE20120550A1
(es)
|
2009-04-07 |
2012-05-21 |
Roche Glycart Ag |
ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
|
|
KR20120053042A
(ko)
|
2009-08-17 |
2012-05-24 |
로슈 글리카트 아게 |
표적화된 면역접합체
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CA2796181C
(en)
|
2010-04-20 |
2023-01-03 |
Genmab A/S |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
SG10201508401TA
(en)
|
2010-10-11 |
2015-11-27 |
Abbvie Bahamas Ltd |
Processes for purification of proteins
|
|
ES2758994T3
(es)
|
2010-11-05 |
2020-05-07 |
Zymeworks Inc |
Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
|
TR201815863T4
(tr)
|
2010-11-30 |
2018-11-21 |
Chugai Pharmaceutical Co Ltd |
Sitotoksisiteyi indükleyen terapötik madde.
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
HUE040326T2
(hu)
|
2011-02-10 |
2019-03-28 |
Roche Glycart Ag |
Mutáns interleukon-2 polipeptidek
|
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
PT2714718T
(pt)
|
2011-05-24 |
2017-04-19 |
Symic Ip Llc |
Preparação e métodos de utilização de peptidoglicanas sintéticas que se ligam a ácido hialurónico
|
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
WO2013053775A1
(en)
|
2011-10-11 |
2013-04-18 |
Universität Zürich Prorektorat Mnw |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
|
US9795686B2
(en)
|
2012-01-19 |
2017-10-24 |
The Johns Hopkins University |
Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
|
|
ES2740749T3
(es)
|
2012-04-20 |
2020-02-06 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
WO2013163766A1
(en)
|
2012-05-04 |
2013-11-07 |
Cangene Corporation |
ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
|
|
EP2880169B1
(en)
|
2012-08-02 |
2017-05-17 |
F. Hoffmann-La Roche AG |
Method for producing monomeric and multimeric molecules and uses thereof
|
|
PL2880170T3
(pl)
|
2012-08-02 |
2017-02-28 |
F.Hoffmann-La Roche Ag |
SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
|
EP3878964A1
(en)
|
2012-11-27 |
2021-09-15 |
Ajou University Industry-Academic Cooperation Foundation |
Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
ES2821753T3
(es)
|
2013-03-15 |
2021-04-27 |
Lilly Co Eli |
Procedimientos de producción de Fab y de anticuerpos biespecíficos
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
HUE039291T2
(hu)
|
2013-03-15 |
2018-12-28 |
Hoffmann La Roche |
IL-22 polipeptidek és IL-22 FC fúziós fehérjék és alkalmazási eljárások
|
|
CN105164157B
(zh)
|
2013-04-29 |
2024-05-28 |
豪夫迈·罗氏有限公司 |
Fc-受体结合的修饰的非对称抗体及使用方法
|
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
WO2015171822A1
(en)
|
2014-05-06 |
2015-11-12 |
Genentech, Inc. |
Production of heteromultimeric proteins using mammalian cells
|
|
KR101721295B1
(ko)
|
2014-06-11 |
2017-04-10 |
주식회사 엘지화학 |
염화비닐계 수지의 제조방법
|
|
JP6822849B2
(ja)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的ＮＫｐ４６結合タンパク質
|
|
HRP20191766T1
(hr)
|
2014-11-06 |
2019-12-27 |
F. Hoffmann - La Roche Ag |
Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene
|
|
EP3842453A1
(en)
|
2014-11-06 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
CN104628870A
(zh)
*
|
2015-02-04 |
2015-05-20 |
中国药科大学 |
一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
|
|
ES2881771T3
(es)
|
2015-08-07 |
2021-11-30 |
Alx Oncology Inc |
Constructos que tienen un dominio de SIRP-alfa o variante del mismo
|
|
RU2770001C2
(ru)
|
2015-10-06 |
2022-04-14 |
Риджентс Оф Дзе Юниверсити Оф Миннесота |
Терапевтические соединения и способы
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
EP3511340B1
(en)
*
|
2016-08-10 |
2024-10-02 |
Ajou University Industry-Academic Cooperation Foundation |
Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
|
|
WO2018030806A1
(ko)
|
2016-08-10 |
2018-02-15 |
아주대학교산학협력단 |
항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
|
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
|
MA46534A
(fr)
|
2016-10-14 |
2019-08-21 |
Xencor Inc |
Protéines de fusion fc hétérodimères il15/il15r
|
|
SG11201907646YA
(en)
|
2017-02-20 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Proteins binding her2, nkg2d and cd16
|
|
ES3010117T3
(en)
|
2017-03-27 |
2025-04-01 |
Hoffmann La Roche |
Improved antigen binding receptors
|
|
KR102286411B1
(ko)
|
2017-05-11 |
2021-08-05 |
이엠디 밀리포어 코포레이션 |
연속 유동 시스템에서 좁은 체류 시간 분포를 유지하기 위한 방법
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
CA3066893A1
(en)
|
2017-06-21 |
2018-12-27 |
Cephalon, Inc. |
Cation exchange chromatography wash buffer
|
|
JP2019014449A
(ja)
|
2017-07-10 |
2019-01-31 |
トヨタ自動車株式会社 |
車両用動力伝達装置
|
|
US20200277383A1
(en)
|
2017-09-07 |
2020-09-03 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
SG11202001772SA
(en)
|
2017-09-21 |
2020-04-29 |
Merck Patent Gmbh |
Fusion protein comprising an fgf-18 moiety
|
|
KR102839644B1
(ko)
|
2017-09-22 |
2025-07-31 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 이중특이적 폴리펩티드 복합체
|
|
JP7450535B2
(ja)
|
2017-10-20 |
2024-03-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
単一特異性抗体から多重特異性抗体を生成させるための方法
|
|
WO2020014486A1
(en)
|
2018-07-11 |
2020-01-16 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc-antigen binding domain constructs
|
|
JP7612571B2
(ja)
|
2018-10-03 |
2025-01-14 |
ゼンコア インコーポレイテッド |
Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
|
|
KR20210080460A
(ko)
|
2018-10-23 |
2021-06-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
이종이량체성 Fc-융합된 단백질
|